Published in J Vis Exp on March 01, 2011
Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 18.74
The inflammasomes: guardians of the body. Annu Rev Immunol (2009) 12.89
The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol (2009) 7.80
Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol (2009) 5.91
The IL-1 family: regulators of immunity. Nat Rev Immunol (2010) 4.65
Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood (2008) 4.63
The inflammasomes: mechanisms of activation and function. Curr Opin Immunol (2010) 3.41
IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol (2010) 2.99
Measurement of cytokine production using whole blood. Curr Protoc Immunol (2005) 0.91
Chemokine production and pattern recognition receptor (PRR) expression in whole blood stimulated with pathogen-associated molecular patterns (PAMPs). Cytokine (2006) 0.91
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell (2002) 5.44
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum (2002) 4.98
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med (2009) 4.97
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood (2006) 4.63
Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat Immunol (2002) 3.60
Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet (2010) 3.24
Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science (2002) 3.05
Autoinflammatory disease reloaded: a clinical perspective. Cell (2010) 3.04
Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol (2003) 2.93
The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature (2012) 2.87
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol (2011) 2.59
Magnetic resonance imaging in the evaluation of bone damage in rheumatoid arthritis: a more precise image or just a more expensive one? Arthritis Rheum (2003) 2.37
PSORS2 is due to mutations in CARD14. Am J Hum Genet (2012) 2.10
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum (2012) 1.87
IL-1 family nomenclature. Nat Immunol (2010) 1.79
STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci U S A (2002) 1.69
Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. J Virol (2007) 1.67
High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum (2011) 1.61
A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum (2008) 1.46
The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med (2015) 1.42
Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum (2003) 1.41
Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol (2013) 1.40
Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum (2012) 1.40
Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr Opin Allergy Clin Immunol (2002) 1.40
Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A (2011) 1.33
S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum (2008) 1.33
G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. J Immunol (2005) 1.28
Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther (2009) 1.27
Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Curr Opin Rheumatol (2010) 1.23
Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol (2006) 1.17
Detection of base substitution-type somatic mosaicism of the NLRP3 gene with >99.9% statistical confidence by massively parallel sequencing. DNA Res (2012) 1.16
USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity. J Biol Chem (2009) 1.14
IL-1 blockade in autoinflammatory syndromes. Annu Rev Med (2014) 1.10
Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis (2012) 1.10
Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol (2015) 1.08
Consequences of disease-causing mutations on lubricin protein synthesis, secretion, and post-translational processing. J Biol Chem (2005) 1.08
Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol (2014) 1.05
A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum (2011) 1.04
Cybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity. Proc Natl Acad Sci U S A (2002) 1.02
Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci (2009) 1.02
Protein kinase A regulates caspase-1 via Ets-1 in bone stromal cell-derived lesions: a link between cyclic AMP and pro-inflammatory pathways in osteoblast progenitors. Hum Mol Genet (2010) 1.02
The newest interleukins: recent additions to the ever-growing cytokine family. Vitam Horm (2006) 0.99
Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep (2012) 0.98
Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation. Rheum Dis Clin North Am (2013) 0.98
A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Ann Rheum Dis (2010) 0.96
Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol (2004) 0.95
Cytokine signaling: birth of a pathway. J Immunol (2011) 0.95
CXCL12 signaling is independent of Jak2 and Jak3. J Biol Chem (2004) 0.95
The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies. Curr Allergy Asthma Rep (2008) 0.94
Viral FLIP impairs survival of activated T cells and generation of CD8+ T cell memory. J Immunol (2004) 0.94
Deficiency of interleukin-1 receptor antagonist responsive to anakinra. Pediatr Dermatol (2012) 0.93
The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates. J Neuroimmunol (2010) 0.93
Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J Immunol (2014) 0.92
Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol (2012) 0.92
Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest (2015) 0.90
The spectrum of autoinflammatory diseases: recent bench to bedside observations. Curr Opin Rheumatol (2008) 0.90
Mutational analysis in neonatal-onset multisystem inflammatory disease: comment on the articles by Frenkel et al and Saito et al. Arthritis Rheum (2006) 0.88
Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Res Ther (2003) 0.88
Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations. Otolaryngol Head Neck Surg (2011) 0.86
A novel mutation in the interleukin-1 receptor antagonist associated with intrauterine disease onset. Clin Immunol (2012) 0.85
Cytohesin binder and regulator (cybr) is not essential for T- and dendritic-cell activation and differentiation. Mol Cell Biol (2006) 0.85
DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name? Arch Dermatol (2012) 0.84
Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. Clin Immunol (2010) 0.84
Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1β. PLoS One (2012) 0.84
Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J Immunol (2011) 0.83
Diurnal secretion of growth hormone, cortisol, and dehydroepiandrosterone in pre- and perimenopausal women with active rheumatoid arthritis: a pilot case-control study. Arthritis Res Ther (2007) 0.82
Use of biologics in rheumatoid arthritis: where are we going? Am J Health Syst Pharm (2006) 0.82
Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts. Ann Rheum Dis (2012) 0.82
Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. Ann Pharmacother (2009) 0.82
Ubiquitination for activation: new directions in the NF-kappaB roadmap. Mol Interv (2004) 0.81
Treatment of patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome: comment on the article by Matsubara et al. Arthritis Rheum (2007) 0.81
Cytohesin binder and regulator augments T cell receptor-induced nuclear factor of activated T Cells.AP-1 activation through regulation of the JNK pathway. J Biol Chem (2006) 0.81
New monogenic autoinflammatory diseases--a clinical overview. Semin Immunopathol (2015) 0.81
Xenotropic murine leukemia virus-related virus is not associated with chronic fatigue syndrome in patients from different areas of the us in the 1990s. Virol J (2011) 0.80
The anesthetic management of children with neonatal-onset multi-system inflammatory disease. Anesth Analg (2007) 0.79
The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs (2013) 0.78
A case of proteasome-associated auto-inflammatory syndrome with compound heterozygous mutations. J Am Acad Dermatol (2013) 0.78
Immunodeficiency is a tough nut to CRAC: the importance of calcium flux in T cell activation. Mol Interv (2006) 0.77
Histologic and Immunohistochemical Features of the Skin Lesions in CANDLE Syndrome. Am J Dermatopathol (2015) 0.77
Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest (2016) 0.77
Newly recognized Mendelian disorders with rheumatic manifestations. Curr Opin Rheumatol (2015) 0.76
Pilot clinical trial of intravenous doxycycline versus placebo for rheumatoid arthritis. J Rheumatol (2003) 0.76
A recurrent rash with fever and arthropathy. J Am Acad Dermatol (2006) 0.75
Periarticular bone findings in rheumatoid arthritis: T2-weighted versus contrast-enhanced T1-weighted MRI. AJR Am J Roentgenol (2006) 0.75